Organon & Co. (OGN)

NYQ – Real vaqt narxi. Valyuta: USD

13.31

-0.02 (-0.15%)

Yopilishda: May 12, 2026, 4:00 PM EDT

13.30

-0.00 (-0.02%)

Bozor oldidan: May 13, 2026, 8:10 AM EDT

05.05.2026

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

04.05.2026

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

30.04.2026

Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

30.04.2026

Organon (OGN) Q1 Earnings and Revenues Miss Estimates

Organon (OGN) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $1.02 per share a year ago.

30.04.2026

Organon Reports Results for the First Quarter Ended March 31, 2026

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions Q1 2026 Q1 2025 VPY VPY ex-FX Women's Health $ 389 $ 463 (16)% (19)% General Medicines Biosimilars 173 141 23% 21% Established Brands 880 887 (1)% (7)% Other (1) 18 22 (15)% (21)% Revenue $ 1,460 $ 1,513 (4)% (9)% Totals may not foot due to rounding.

29.04.2026

Organon Cancels First Quarter Earnings Call

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue.

28.04.2026

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
OGN	Evercore ISI	In-line	undefined >> undefined	May 2nd 2025
OGN	JP Morgan	Underweight	$18 >> $20	September 6th 2024
OGN	Goldman	Neutral	$33 >> $16	November 3rd 2023
OGN	Barclays	Overweight	undefined >> $28	September 21st 2023
OGN	Raymond James	Outperform	undefined >> $33	March 16th 2023
OGN	BofA Securities	Underperform	$27 >> $25	October 14th 2022
OGN	Piper Sandler	Overweight	$37 >> $34	September 6th 2022
OGN	Goldman	Buy	undefined >> $40	April 27th 2022

Press-relizlar

05.05.2026

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

30.04.2026

Organon Reports Results for the First Quarter Ended March 31, 2026

29.04.2026

Organon Cancels First Quarter Earnings Call

28.04.2026

Organon & Co. (OGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Organon & Co. (OGN)

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Organon (OGN) Q1 Earnings and Revenues Miss Estimates

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Organon (OGN) Q1 Earnings and Revenues Miss Estimates

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Search stocks

Organon & Co. (OGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Organon & Co. (OGN)

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Organon (OGN) Q1 Earnings and Revenues Miss Estimates

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Organon (OGN) Q1 Earnings and Revenues Miss Estimates

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN